European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. billion in 2031.

Labelling 98

Labelling Compounding 98

Pharmaceutical Technology

JULY 26, 2022

The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Compounding 122

Compounding Labelling 122

pharmaphorum

MARCH 14, 2022

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Sponsored by: CHDR. Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc. The global Postoperative Pain Therapeutics Market was valued at USD 11.26

Compounding 52

Compounding 52

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23

Compounding 98

Compounding Pharmaceutical Companies Pharmaceutical Companies Communication 98

pharmaphorum

JUNE 2, 2022

By 2026, the report predicts that each of the top 10 selling orphan drugs will earn between $3 billion and $13 billion. The report estimates that the orphan drug market will grow twice as fast as the non-orphan market, with a 2021 to 2026 compound annual growth rate of 12%.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 18, 2023

AI-based medical imaging was a market worth more than $400 million in 2021, according to figures cited by Bayer, and is expected to have a compound annual growth rate (CAGR) of more than 26% between 2020 to 2026, driving its value to around $1.36

Compounding 59

Compounding 59

PharmaShots

FEBRUARY 22, 2023

In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Hence, it needs to protect its patent as Trulicity patents are very vital to the company’s business as a whole.

Insurance 64

Insurance Compounding Dosage Communication 64

pharmaphorum

APRIL 24, 2022

In a statement, the drugmaker said “we stand by the safety of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound.”

Compounding 52

Compounding FDA 52

Fuld

FEBRUARY 18, 2019

We’ve included a brief summary regarding the role of AI in the workplace and offered advice that depicts how the landscape has shifted in 2018 and explain how a tech company might begin to leverage AI in a balanced way that grows efficiencies without realizing many employees’ greatest fears—being replaced by robots.

Compounding 65

Compounding Communication 65

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9 billion in sales in 2019, increasing to $136.2

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Blog: Ask a Student Pharmacist

JUNE 21, 2023

Jiashu Xie, PhD eomizowh Wed, 06/21/2023 - 10:11 Expand all + Biography Research Summary Current research in the Pharmacokinetics (PK) lab has focused on profiling the in vitro ADME (absorption, distribution, metabolism, and excretion) and in vivo PK properties of lead compounds from medicinal chemistry efforts.

Compounding 40

Compounding Chemotherapy Immunization 40

Pharmacy Times

JUNE 4, 2025

USP labs provide unparalleled expertise in developing quality and process standards, establishing and validating analytical methods, characterizing impurities, and synthesizing organic compounds. USP plans to continue expanding its advanced technology footprint into an additional 8,000 square foot laboratory in 2026. Subscribe Now!

Compounding Pharmacies 65

Compounding Pharmacies Compounding Immunization Specialty Pharmacies 65

The FDA Law Blog

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The Discount Program is similar to the CGDP with respect to several requirements and operational processes, and CMS will implement it in a similar manner.

Labelling 105

Labelling Compounding Payment Processing Vaccines 105

Druggist

APRIL 29, 2021

Eliquis is still protected by patent rights in the UK, with exclusive availability rights until 2026 (IPO, 2021). . Apixaban stops the production of enzymes (chemicals) required for the production of fibrin , a compound (protein) that plays a role in the clotting of the blood. Apixaban vs warfarin: differences in licensed use.

Chemotherapy 98

Chemotherapy Documentation Compounding Dosage 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

According to a report by Research Nester, the global aseptic packaging market is projected to reach a revenue of $35 billion by 2033 and is estimated to reach a compound annual growth rate (CAGR) of 10 percent between 2023 and 2033. According to the report, European production has grown by approximately 5.4 percent annually in recent years.

Packaging 105

Packaging Vaccines Compounding 105

Viseven

SEPTEMBER 18, 2024

By the end of 2026, the company will be able to analyze two million genomes. It is no surprise that the global market is growing at a compound annual rate of 20%. This innovative approach has brought more than 40 successful drug discovery projects to AstraZeneca.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 52